Epigenomics AG Reports Financial Results for Fiscal Year 2006
30 mars 2007 02h44 HE
|
Epigenomics AG
* Financials in line with latest expectations:
- Full year revenue EUR 3.5 million, EBIT at EUR -15.8 million
- Operational costs EUR 21.2 million
- Liquidity of EUR 17.3 million as of...
Epigenomics AG to Host Press Conference and Analyst Meeting for 2006 Annual Results
22 mars 2007 06h19 HE
|
Epigenomics AG
BERLIN, Germany and SEATTLE, March 22, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Other OTC:EPGNF) (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company, will hold its annual press...
Epigenomics AG: Clinical Data Show That Colon Polyps Can be Detected With Simple Blood Test
20 mars 2007 03h41 HE
|
Epigenomics AG
BERLIN and SEATTLE, March 20, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), a cancer molecular diagnostics company, announced that Prof. Dr. Matthias Ebert, gastroenterologist at the...
Epigenomics AG: Heino Von Prondzynski to Stand for Election Into Supervisory Board
05 mars 2007 02h37 HE
|
Epigenomics AG
BERLIN and SEATTLE, March 5, 2007 (PRIME NEWSWIRE) -- At its meeting on March 1st, the Supervisory Board of Epigenomics AG (Frankfurt:ECX) decided to propose Heino von Prondzynski for election to the...
Hugin Ad Hoc Announcement According to Section 15 WpHG: Board of Directors: Epigenomics AG Appoints Senior Abbott-Executive Geert Walther Nygaard as New CEO
16 janv. 2007 02h53 HE
|
Epigenomics AG
BERLIN and SEATTLE, Jan. 16, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) today announced that its Supervisory Board has unanimously decided to appoint Geert Walther Nygaard as the...
Epigenomics AG to Discover Biomarkers in R&D Collaboration With Centocor Inc.
04 janv. 2007 02h47 HE
|
Epigenomics AG
BERLIN, Germany, Jan. 4, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), (Other OTC:EPGNF) has entered into an R&D collaboration with Centocor Inc., a US-based, biomedicines company, to...
Hugin Ad Hoc Announcement According to Section 15 WpHG: Contract: Epigenomics AG: Epigenomics AG Reviews All Options for the Commercialization of Cancer Screening Test Products After End of Collaboration With Roche Diagnostics
15 déc. 2006 03h05 HE
|
Epigenomics AG
-- Roche Diagnostics notified Epigenomics about the termination of the
joint collaboration on screening tests for early detection of cancer
and returns licensed marker Septin 9
--...
Epigenomics AG: PITX2 Prostate Cancer Molecular Classification Test Successfully Transferred to Affymetrix Diagnostic Platform
12 déc. 2006 03h25 HE
|
Epigenomics AG
-- Concordance study demonstrated excellent agreement between
Epigenomics' chosen commercial diagnostic test platform and
prototype research assays.
-- Based on a prior FDA Early...
Epigenomics AG Reports Third Quarter 2006 Results
02 nov. 2006 02h44 HE
|
Epigenomics AG
-- Business Fundamentals and Product Development well on Track
-- Search for CEO under way - completion expected by year-end
-- Cash position in line with guidance; revenue and earnings
...
Hugin Ad Hoc Announcement According to Section 15 WpHG: Misc. Strategic Decisions: Epigenomics AG: Focus on Late Stage Product Development
26 oct. 2006 02h24 HE
|
Epigenomics AG
-- Berlin Operations Streamlined -- Workforce Reduced by 34 Positions
-- Business Strategy Unchanged -- Focus on Key Value Drivers
BERLIN and SEATTLE, Oct. 26, 2006 (PRIMEZONE) -- Epigenomics...